{"transactions":[{"id":819288,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":3,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":4,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Second Amended and Restated Convertible Promissory Note","published_at":"2026-04-03T00:08:43.000Z","date":"2026-03-31","kind":"exercise","planned":false,"acquired":false,"price":0,"reported_value":25000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Nant Capital has the right at any time after December 10, 2024 and on or before December 31, 2027 to convert all or a portion of the outstanding principal amount of this Second Amended and Restated Promissory Note, as amended January 23, 2026, into fully paid and nonassessable shares of the Issuer's common stock at a price per share equal to $5.427. On March 31, 2026, Nant Capital delivered notice to the Issuer electing to convert outstanding principal in the amount of $25,000,000 into 4,606,596 shares of the Issuer's common stock."},{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F9","text":"Nant Capital has the right at any time after December 10, 2024 and on or before December 31, 2027 to convert all or a portion of the outstanding principal amount of this Second Amended and Restated Promissory Note, as amended January 23, 2026, into fully paid and nonassessable shares of the Issuer's common stock at a price per share equal to $5.427. On March 31, 2026, Nant Capital delivered notice to the Issuer electing to convert outstanding principal in the amount of $25,000,000 into 4,606,596 shares of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Nant Capital, LLC, an investment vehicle of the Reporting Person."}],"derivative":{"exercise_price":5.427,"exercise_date":"2024-12-10","expiration_date":"2027-12-31","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001189020-26-000008","document":"wk-form4_1775174919.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000118902026000008/wk-form4_1775174919.xml","form_type":"4"}},{"id":819287,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":3,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":4,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T00:08:43.000Z","date":"2026-03-31","kind":"exercise","planned":false,"acquired":true,"shares":4606596,"price":5.427,"value":24999996.492,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Nant Capital, LLC, an investment vehicle of the Reporting Person."}],"balance_after":251018873,"source":{"system":"sec-edgar","filing":"0001189020-26-000008","document":"wk-form4_1775174919.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000118902026000008/wk-form4_1775174919.xml","form_type":"4"}},{"id":884462,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":3,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":4,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-02-25T01:05:07.000Z","date":"2026-02-22","kind":"exercise","planned":false,"acquired":false,"shares":114329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."}],"balance_after":114329,"derivative":{"underlying":"Common Stock","underlying_shares":114329},"source":{"system":"sec-edgar","filing":"0001189020-26-000006","document":"wk-form4_1771981503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000118902026000006/wk-form4_1771981503.xml","form_type":"4"}},{"id":884461,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":3,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":4,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-25T01:05:07.000Z","date":"2026-02-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":58170,"price":8.7,"value":506079.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld."}],"balance_after":29757911,"source":{"system":"sec-edgar","filing":"0001189020-26-000006","document":"wk-form4_1771981503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000118902026000006/wk-form4_1771981503.xml","form_type":"4"}},{"id":884460,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":3,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":4,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-25T01:05:07.000Z","date":"2026-02-22","kind":"exercise","planned":false,"acquired":true,"shares":114329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":29816081,"source":{"system":"sec-edgar","filing":"0001189020-26-000006","document":"wk-form4_1771981503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000118902026000006/wk-form4_1771981503.xml","form_type":"4"}},{"id":907423,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":3,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":4,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-02-13T02:29:23.000Z","date":"2026-02-10","kind":"exercise","planned":false,"acquired":false,"shares":274122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025."}],"balance_after":548246,"derivative":{"underlying":"Common Stock","underlying_shares":274122},"source":{"system":"sec-edgar","filing":"0001189020-26-000003","document":"wk-form4_1770949759.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000118902026000003/wk-form4_1770949759.xml","form_type":"4"}},{"id":907422,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":3,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":4,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-13T02:29:23.000Z","date":"2026-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":118560,"price":6.93,"value":821620.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 10, 2026, the reporting person's RSUs vested. The closing price of the Issuer's common stock on February 9, 2026 was the settlement price used to calculate the shares withheld."}],"balance_after":29701752,"source":{"system":"sec-edgar","filing":"0001189020-26-000003","document":"wk-form4_1770949759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000118902026000003/wk-form4_1770949759.xml","form_type":"4"}},{"id":907421,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":3,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":4,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-13T02:29:23.000Z","date":"2026-02-10","kind":"exercise","planned":false,"acquired":true,"shares":274122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":29820312,"source":{"system":"sec-edgar","filing":"0001189020-26-000003","document":"wk-form4_1770949759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000118902026000003/wk-form4_1770949759.xml","form_type":"4"}},{"id":1245773,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":4,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-02-26T02:11:37.000Z","date":"2025-02-22","kind":"exercise","planned":false,"acquired":false,"shares":114329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."}],"balance_after":228658,"derivative":{"underlying":"Common Stock","underlying_shares":114329},"source":{"system":"sec-edgar","filing":"0001326110-25-000023","document":"wk-form4_1740535889.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000023/wk-form4_1740535889.xml","form_type":"4"}},{"id":1245772,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":4,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-26T02:11:37.000Z","date":"2025-02-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":42071,"price":3.42,"value":143882.82,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 22, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 21, 2025 was the settlement price used to calculate the shares withheld."}],"balance_after":29546190,"source":{"system":"sec-edgar","filing":"0001326110-25-000023","document":"wk-form4_1740535889.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000023/wk-form4_1740535889.xml","form_type":"4"}},{"id":1245771,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":4,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-26T02:11:37.000Z","date":"2025-02-22","kind":"exercise","planned":false,"acquired":true,"shares":114329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":29588261,"source":{"system":"sec-edgar","filing":"0001326110-25-000023","document":"wk-form4_1740535889.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000023/wk-form4_1740535889.xml","form_type":"4"}},{"id":1271420,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-13T01:17:09.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":2812500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the option shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the option shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is February 10, 2025."}],"balance_after":2812500,"derivative":{"exercise_price":3.39,"expiration_date":"2035-02-10","underlying":"Common Stock","underlying_shares":2812500},"source":{"system":"sec-edgar","filing":"0001326110-25-000014","document":"wk-form4_1739409423.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000014/wk-form4_1739409423.xml","form_type":"4"}},{"id":1271419,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}}],"security":"Restricted Stock Units","published_at":"2025-02-13T01:17:09.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":822368,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025."}],"balance_after":822368,"derivative":{"underlying":"Common Stock","underlying_shares":822368},"source":{"system":"sec-edgar","filing":"0001326110-25-000014","document":"wk-form4_1739409423.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000014/wk-form4_1739409423.xml","form_type":"4"}},{"id":1333681,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":4,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Second Amended and Restated Convertible Promissory Note","published_at":"2024-12-13T02:20:26.000Z","date":"2024-12-10","kind":"other","planned":false,"acquired":true,"price":505000000,"reported_value":505000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"On December 10, 2024, Nant Capital and the Issuer entered into a Second Amended and Restated Promissory Note pursuant to which the Issuer and Nant Capital agreed to consolidate remaining outstanding notes held by Nant Capital into one consolidated $505.0 million note (the \"Consolidated Note\" and such transaction, the \"Debt Restructuring\"). The principal amount of the Consolidated Note shall be convertible in full (and not partially) at Nant Capital's option, at a price per share equal to $5.427 (subject to appropriate adjustment from time to time for any stock dividend, stock split, combination of shares, reorganization, recapitalization, reclassification or other similar event)."},{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F13","text":"On December 10, 2024, Nant Capital and the Issuer entered into a Second Amended and Restated Promissory Note pursuant to which the Issuer and Nant Capital agreed to consolidate remaining outstanding notes held by Nant Capital into one consolidated $505.0 million note (the \"Consolidated Note\" and such transaction, the \"Debt Restructuring\"). The principal amount of the Consolidated Note shall be convertible in full (and not partially) at Nant Capital's option, at a price per share equal to $5.427 (subject to appropriate adjustment from time to time for any stock dividend, stock split, combination of shares, reorganization, recapitalization, reclassification or other similar event)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The Consolidated Note held by Nant Capital."}],"derivative":{"exercise_price":5.427,"exercise_date":"2024-12-10","expiration_date":"2027-12-31","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001326110-24-000117","document":"wk-form4_1734056418.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000117/wk-form4_1734056418.xml","form_type":"4"}},{"id":1333680,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":4,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Amended and Restated Promissory Note","published_at":"2024-12-13T02:20:26.000Z","date":"2024-12-10","kind":"other","planned":false,"acquired":false,"price":0,"reported_value":380000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"On December 10, 2024, Nant Capital and the Issuer entered into a Second Amended and Restated Promissory Note pursuant to which the Issuer and Nant Capital agreed to consolidate remaining outstanding notes held by Nant Capital into one consolidated $505.0 million note (the \"Consolidated Note\" and such transaction, the \"Debt Restructuring\"). The principal amount of the Consolidated Note shall be convertible in full (and not partially) at Nant Capital's option, at a price per share equal to $5.427 (subject to appropriate adjustment from time to time for any stock dividend, stock split, combination of shares, reorganization, recapitalization, reclassification or other similar event)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"Amended and Restated Convertible Promissory Note held by Nant Capital."}],"derivative":{"exercise_price":8.27,"exercise_date":"2023-12-29","expiration_date":"2025-12-31","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001326110-24-000117","document":"wk-form4_1734056418.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000117/wk-form4_1734056418.xml","form_type":"4"}},{"id":1333679,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":4,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2024-12-13T02:20:26.000Z","date":"2024-12-10","kind":"exercise","planned":false,"acquired":false,"price":0,"reported_value":30000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F12","text":"Nant Capital has the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under such Convertible Promissory Note at the time of conversion into shares of the Issuer's common stock at a price of $2.28 per share. On December 10, 2024, Nant Capital delivered notice to the Issuer that they elected to convert the outstanding principal and all accrued and unpaid interest in the amount of $30,723,395.57 into 13,475,172 shares if the Issuer's common stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F12","text":"Nant Capital has the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under such Convertible Promissory Note at the time of conversion into shares of the Issuer's common stock at a price of $2.28 per share. On December 10, 2024, Nant Capital delivered notice to the Issuer that they elected to convert the outstanding principal and all accrued and unpaid interest in the amount of $30,723,395.57 into 13,475,172 shares if the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"Convertible Promissory Note held by Nant Capital."}],"derivative":{"exercise_price":2.28,"exercise_date":"2023-05-12","expiration_date":"2025-12-31","underlying":"Common Stock","underlying_shares":13475172},"source":{"system":"sec-edgar","filing":"0001326110-24-000117","document":"wk-form4_1734056418.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000117/wk-form4_1734056418.xml","form_type":"4"}},{"id":1333678,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":4,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2024-12-13T02:20:26.000Z","date":"2024-12-10","kind":"exercise","planned":false,"acquired":false,"price":0,"reported_value":200000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Nant Capital  has the right at any time after the Conversion Date (as defined in the Convertible Promissory Note (the \"Note\")) and on or before September 11, 2026 to convert all (but not less than all) of the outstanding principal amount of this Note and all (but not less than all) accrued and unpaid interest on this Note into fully paid and nonassessable shares of the Issuer's common stock at a price per share equal to $1.935.  On December 10, 2024, Nant Capital delivered notice to the Issuer that they elected to convert the outstanding principal and all accrued and unpaid interest in the amount of $200,679,022.30 into 103,710,088 shares if the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"That date upon which an amendment to the Issuers Certificate of Incorporation, as amended, becomes effective pursuant to which the number of authorized shares of the Issuer's common stock is increased from 900,000,000 to 1,350,000,000."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F9","text":"Nant Capital  has the right at any time after the Conversion Date (as defined in the Convertible Promissory Note (the \"Note\")) and on or before September 11, 2026 to convert all (but not less than all) of the outstanding principal amount of this Note and all (but not less than all) accrued and unpaid interest on this Note into fully paid and nonassessable shares of the Issuer's common stock at a price per share equal to $1.935.  On December 10, 2024, Nant Capital delivered notice to the Issuer that they elected to convert the outstanding principal and all accrued and unpaid interest in the amount of $200,679,022.30 into 103,710,088 shares if the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"Convertible Promissory Note held by Nant Capital."}],"derivative":{"exercise_price":1.935,"expiration_date":"2026-09-11","underlying":"Common Stock","underlying_shares":103710088},"source":{"system":"sec-edgar","filing":"0001326110-24-000117","document":"wk-form4_1734056418.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000117/wk-form4_1734056418.xml","form_type":"4"}},{"id":1333677,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":4,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-13T02:20:26.000Z","date":"2024-12-10","kind":"exercise","planned":false,"acquired":true,"shares":13475172,"price":2.28,"value":30723392.16,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Nant Capital, LLC, an investment vehicle of the reporting person (\"Nant Capital\")."}],"balance_after":246412277,"source":{"system":"sec-edgar","filing":"0001326110-24-000117","document":"wk-form4_1734056418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000117/wk-form4_1734056418.xml","form_type":"4"}},{"id":1333676,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":4,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-13T02:20:26.000Z","date":"2024-12-10","kind":"exercise","planned":false,"acquired":true,"shares":103710088,"price":1.935,"value":200679020.28,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Nant Capital, LLC, an investment vehicle of the reporting person (\"Nant Capital\")."}],"balance_after":232937105,"source":{"system":"sec-edgar","filing":"0001326110-24-000117","document":"wk-form4_1734056418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000117/wk-form4_1734056418.xml","form_type":"4"}},{"id":1359916,"issuer":{"id":11460,"kind":"organization","name":"Panbela Therapeutics, Inc.","symbol":"PBLA"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":2,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"8% Senior Convertible Note due 2025","published_at":"2024-11-19T18:40:08.000Z","date":"2024-11-15","kind":"purchase","planned":false,"acquired":true,"price":9150000,"reported_value":9150000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The holding includes the 8% Senior Convertible Tranche A Note issued on October 22, 2024 (\"Tranche A Note\") as previously reported on the Form 3 filed on October 29, 2024, and the 8% Senior Convertible Tranche B Note issued on November 15, 2024 (the \"Tranche B Note\"), in each case issued pursuant to that certain Note Purchase Agreement by and between the Issuer and Nant Capital, LLC (\"Nant Capital\") dated October 22, 2024 (the \"Purchase Agreement\"). The Tranche A Note and the Tranche B Note are reported as a single holding (the \"Note\"). Interest accrues on the unpaid principal amount at a rate equal to 8.0% plus the Monthly SOFR Rate (as defined in the Note), which shall be due and payable in full on April 22, 2025 (the \"Maturity Date\")"},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Subject to an issuance limitation in the event of a voluntary conversion of the Note occurring prior to the Maturity Date that prohibits Nant Capital from converting the Note to the extent that after giving effect to the issuance of the Issuer's common stock after such conversion, Nant Capital (together with Nant Capital's affiliates, and any other person acting as a group together with Nant Capital or any of Nant Capital's affiliates) would beneficially own in excess of 33.33% of the shares of the Issuer's common stock outstanding. If the Note has not previously been repaid in full in cash or converted in full into shares of the Issuer's common stock on or before the Maturity Date, Nant Capital will have the right to convert each Note in full, including accrued but unpaid interest, at Nant Capital's sole discretion, at a conversion price of $0.37."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F3","text":"Includes the Tranche A Note of $2,850,000 principal amount as previously reported on the Form 3."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Note held by Nant Capital. Dr. Patrick Soon-Shiong owns all of the equity interests of Nant Capital and Dr. Soon-Shiong may be deemed to have beneficial ownership of the shares held by Nant Capital."}],"derivative":{"exercise_price":0.37,"exercise_date":"2024-11-15","expiration_date":"2025-04-22","underlying":"Common Stock","underlying_shares":24729730},"source":{"system":"sec-edgar","filing":"0000950170-24-128924","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029125/000095017024128924/ownership.xml","form_type":"4"}},{"id":1619045,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-26T21:36:18.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":1193597,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the option shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the option shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is February 22, 2024."}],"balance_after":1193597,"derivative":{"exercise_price":5.24,"expiration_date":"2034-02-22","underlying":"Common Stock","underlying_shares":1193597},"source":{"system":"sec-edgar","filing":"0001326110-24-000024","document":"wk-form4_1708983362.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000024/wk-form4_1708983362.xml","form_type":"4"}},{"id":1619044,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}}],"security":"Restricted Stock Units","published_at":"2024-02-26T21:36:18.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":342987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."}],"balance_after":342987,"derivative":{"underlying":"Common Stock","underlying_shares":342987},"source":{"system":"sec-edgar","filing":"0001326110-24-000024","document":"wk-form4_1708983362.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000024/wk-form4_1708983362.xml","form_type":"4"}},{"id":1633137,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":2,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":3,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":4,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-20T16:51:24.000Z","date":"2024-02-15","kind":"purchase","planned":false,"acquired":true,"shares":442298,"price":1.5195,"value":672071.811,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common Stock of the Issuer acquired by Cambridge Equities, LP (\"Cambridge Equities\") in a private transaction pursuant to a Stock Transfer Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price was calculated based on the OTCQX Best Market volume weighted average closing price of the Issuer's common stock, as reported by OTC Markets Group Inc. during the ten (10) trading day period ending on the trading day prior to the date of sale."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Transaction previously reported on Form 3 jointly filed by Cambridge Equities and MP13 Ventures, LLC (\"MP 13 Ventures\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Shares owned by Cambridge Equities, who is a member of a \"group\" with Nant Capital, LLC (\"Nant Capital\") and Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. MP13 Ventures is the general partner of Cambridge Equities and may be deemed to have beneficial ownership of the shares held by Cambridge Equities and Dr. Patrick Soon-Shiong is the sole member of MP13 Ventures. As a result, MP13 Ventures and Dr. Soon-Shiong may be deemed to beneficially own, and share with Cambridge Equities the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares owned by Cambridge Equities."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"The reporting owners disclaims beneficial ownership over the shares owned, except to the extent of their pecuniary interest."}],"balance_after":442298,"source":{"system":"sec-edgar","filing":"0000950170-24-017225","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000095017024017225/ownership.xml","form_type":"4"}},{"id":1691688,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":2,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2024-01-04T02:53:11.000Z","date":"2023-12-29","kind":"other","planned":false,"acquired":true,"price":30000000,"reported_value":30000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"In connection with the RIPA, the Issuer entered into a letter agreement, dated as of December 29, 2023, pursuant to which the Issuer and Nant Capital agreed to extend the maturity date of an existing convertible promissory note with an aggregate principal amount of approximately $30 million held by Nant Capital from December 31, 2023, as previously reported in the Form 4 filed May 16, 2023, to December 31, 2025.  Nant Capital has the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under such note at the time of conversion into shares of the Issuer's Common Stock at a price of $2.28 per share."},{"field":"reported_value","element":"transactionTotalValue","label":"F3","text":"In connection with the RIPA, the Issuer entered into a letter agreement, dated as of December 29, 2023, pursuant to which the Issuer and Nant Capital agreed to extend the maturity date of an existing convertible promissory note with an aggregate principal amount of approximately $30 million held by Nant Capital from December 31, 2023, as previously reported in the Form 4 filed May 16, 2023, to December 31, 2025.  Nant Capital has the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under such note at the time of conversion into shares of the Issuer's Common Stock at a price of $2.28 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"In connection with the RIPA, the Issuer entered into a letter agreement, dated as of December 29, 2023, pursuant to which the Issuer and Nant Capital agreed to extend the maturity date of an existing convertible promissory note with an aggregate principal amount of approximately $30 million held by Nant Capital from December 31, 2023, as previously reported in the Form 4 filed May 16, 2023, to December 31, 2025.  Nant Capital has the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under such note at the time of conversion into shares of the Issuer's Common Stock at a price of $2.28 per share."},{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F3","text":"In connection with the RIPA, the Issuer entered into a letter agreement, dated as of December 29, 2023, pursuant to which the Issuer and Nant Capital agreed to extend the maturity date of an existing convertible promissory note with an aggregate principal amount of approximately $30 million held by Nant Capital from December 31, 2023, as previously reported in the Form 4 filed May 16, 2023, to December 31, 2025.  Nant Capital has the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under such note at the time of conversion into shares of the Issuer's Common Stock at a price of $2.28 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Convertible Promissory Note, dated as of March 31, 2023, as amended, held by Nant Capital, an investment vehicle of the reporting person."}],"derivative":{"exercise_price":2.28,"exercise_date":"2023-05-12","expiration_date":"2025-12-31","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001326110-24-000009","document":"wk-form4_1704336782.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000009/wk-form4_1704336782.xml","form_type":"4"}},{"id":1691687,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":2,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Amended and Restated Promissory Note","published_at":"2024-01-04T02:53:11.000Z","date":"2023-12-29","kind":"other","planned":false,"acquired":true,"price":380000000,"reported_value":380000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 29, 2023, in connection with the Issuer entering into a Revenue Interest Purchase Agreement with Infinity SA LLC, an affiliate of Oberland Capital Management LLC, as collateral agent and administrative agent for the purchasers party thereto (the \"RIPA\"), the Issuer and Nant Capital, LLC (\"Nant Capital\") entered into an Amended and Restated Promissory Note pursuant to which the Issuer and Nant Capital agreed to extend the maturity dates of certain existing promissory notes held by Nant Capital from December 31, 2024 to December 31, 2025, and to allow Nant Capital, in its sole discretion, to convert up to an aggregate of $380 million of principal, plus accrued and unpaid interest thereon, into shares of Issuer's Common Stock at a price per share equal to $8.27."},{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F1","text":"On December 29, 2023, in connection with the Issuer entering into a Revenue Interest Purchase Agreement with Infinity SA LLC, an affiliate of Oberland Capital Management LLC, as collateral agent and administrative agent for the purchasers party thereto (the \"RIPA\"), the Issuer and Nant Capital, LLC (\"Nant Capital\") entered into an Amended and Restated Promissory Note pursuant to which the Issuer and Nant Capital agreed to extend the maturity dates of certain existing promissory notes held by Nant Capital from December 31, 2024 to December 31, 2025, and to allow Nant Capital, in its sole discretion, to convert up to an aggregate of $380 million of principal, plus accrued and unpaid interest thereon, into shares of Issuer's Common Stock at a price per share equal to $8.27."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Amended and Restated Promissory Note, dated as of December 29, 2023, held by Nant Capital, an investment vehicle of the reporting person."}],"derivative":{"exercise_price":8.27,"exercise_date":"2023-12-29","expiration_date":"2025-12-31","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001326110-24-000009","document":"wk-form4_1704336782.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000009/wk-form4_1704336782.xml","form_type":"4"}},{"id":1781939,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":4,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2023-09-14T01:07:11.000Z","date":"2023-09-11","kind":"purchase","planned":false,"acquired":true,"price":200000000,"reported_value":200000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"That date upon which an amendment to the Issuers Certificate of Incorporation, as amended, becomes effective pursuant to which the number of authorized shares of the Issuer's common stock is increased from 900,000,000 to 1,350,000,000."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F16","text":"Reporting person has the right at any time after the Conversion Date and on or before September 11, 2026 to convert all (but not less than all) of the outstanding principal amount of this Convertible Promissory Note (the \"Note\") and all (but not less than all) accrued and unpaid interest on this Note into fully paid and nonassessable shares of the Issuer's common stock at a price per share equal to $1.935."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F17","text":"Convertible Promissory Note held by Nant Capital, an investment vehicle of the reporting person."}],"derivative":{"exercise_price":1.935,"expiration_date":"2026-09-11","underlying":"Common  Stock"},"source":{"system":"sec-edgar","filing":"0000950170-23-048020","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000095017023048020/ownership.xml","form_type":"4"}},{"id":1781938,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":4,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Second Amended and Restated Convertible Promissory Note","published_at":"2023-09-14T01:07:11.000Z","date":"2023-09-11","kind":"other","planned":false,"acquired":false,"price":0,"reported_value":42063011,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC (\"Nant Capital\"), NantMobile, LLC (\"NantMobile\") and NantCancerStemCell, LLC (\"NCSC\" and together with Nant Capital and NantMobile, the \"Purchasers\"), entered into a Stock Purchase Agreement (the \"SPA\") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the \"Notes,\" at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes."},{"field":"reported_value","element":"transactionTotalValue","label":"F10","text":"Represents the entire outstanding principal amount and accrued and unpaid interest due as of September 8, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC (\"Nant Capital\"), NantMobile, LLC (\"NantMobile\") and NantCancerStemCell, LLC (\"NCSC\" and together with Nant Capital and NantMobile, the \"Purchasers\"), entered into a Stock Purchase Agreement (the \"SPA\") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the \"Notes,\" at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"Second Amended and Restated Convertible Promissory Note held by NCSC. NantBio is the sole stockholder and an affiliate of NCSC and may be deemed to have beneficial ownership of the securities held by NCSC. NantWorks is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the securities held by NantBio and its affiliates. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantBio and its affiliates."}],"derivative":{"exercise_price":5.67,"exercise_date":"2022-08-31","expiration_date":"2025-09-30","underlying":"Common  Stock"},"source":{"system":"sec-edgar","filing":"0000950170-23-048020","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000095017023048020/ownership.xml","form_type":"4"}},{"id":1781937,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":4,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Second Amended and Restated Convertible Promissory Note","published_at":"2023-09-14T01:07:11.000Z","date":"2023-09-11","kind":"other","planned":false,"acquired":false,"price":0,"reported_value":61349735,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC (\"Nant Capital\"), NantMobile, LLC (\"NantMobile\") and NantCancerStemCell, LLC (\"NCSC\" and together with Nant Capital and NantMobile, the \"Purchasers\"), entered into a Stock Purchase Agreement (the \"SPA\") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the \"Notes,\" at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes."},{"field":"reported_value","element":"transactionTotalValue","label":"F10","text":"Represents the entire outstanding principal amount and accrued and unpaid interest due as of September 8, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC (\"Nant Capital\"), NantMobile, LLC (\"NantMobile\") and NantCancerStemCell, LLC (\"NCSC\" and together with Nant Capital and NantMobile, the \"Purchasers\"), entered into a Stock Purchase Agreement (the \"SPA\") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the \"Notes,\" at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"Second Amended and Restated Convertible Promissory Note held by NantMobile. NantWorks is the majority stockholder and an affiliate of NantMobile and may be deemed to have beneficial ownership of the securities held by NantMobile. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantMobile."}],"derivative":{"exercise_price":5.67,"exercise_date":"2022-08-31","expiration_date":"2025-09-30","underlying":"Common  Stock"},"source":{"system":"sec-edgar","filing":"0000950170-23-048020","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000095017023048020/ownership.xml","form_type":"4"}},{"id":1781936,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":4,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Second Amended and Restated Convertible Promissory Note","published_at":"2023-09-14T01:07:11.000Z","date":"2023-09-11","kind":"other","planned":false,"acquired":false,"price":0,"reported_value":66756715,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC (\"Nant Capital\"), NantMobile, LLC (\"NantMobile\") and NantCancerStemCell, LLC (\"NCSC\" and together with Nant Capital and NantMobile, the \"Purchasers\"), entered into a Stock Purchase Agreement (the \"SPA\") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the \"Notes,\" at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes."},{"field":"reported_value","element":"transactionTotalValue","label":"F10","text":"Represents the entire outstanding principal amount and accrued and unpaid interest due as of September 8, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC (\"Nant Capital\"), NantMobile, LLC (\"NantMobile\") and NantCancerStemCell, LLC (\"NCSC\" and together with Nant Capital and NantMobile, the \"Purchasers\"), entered into a Stock Purchase Agreement (the \"SPA\") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the \"Notes,\" at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"Second Amended and Restated Convertible Promissory Note held by Nant Capital, an investment vehicle of the reporting person."}],"derivative":{"exercise_price":5.67,"exercise_date":"2022-08-31","expiration_date":"2025-09-30","underlying":"Common  Stock"},"source":{"system":"sec-edgar","filing":"0000950170-23-048020","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000095017023048020/ownership.xml","form_type":"4"}},{"id":1781935,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":4,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Amended and Restated Convertible Promissory Note","published_at":"2023-09-14T01:07:11.000Z","date":"2023-09-11","kind":"other","planned":false,"acquired":false,"price":0,"reported_value":59356865,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC (\"Nant Capital\"), NantMobile, LLC (\"NantMobile\") and NantCancerStemCell, LLC (\"NCSC\" and together with Nant Capital and NantMobile, the \"Purchasers\"), entered into a Stock Purchase Agreement (the \"SPA\") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the \"Notes,\" at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes."},{"field":"reported_value","element":"transactionTotalValue","label":"F10","text":"Represents the entire outstanding principal amount and accrued and unpaid interest due as of September 8, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC (\"Nant Capital\"), NantMobile, LLC (\"NantMobile\") and NantCancerStemCell, LLC (\"NCSC\" and together with Nant Capital and NantMobile, the \"Purchasers\"), entered into a Stock Purchase Agreement (the \"SPA\") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the \"Notes,\" at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"Amended and Restated Convertible Promissory Note held by Nant Capital, an investment vehicle of the reporting person."}],"derivative":{"exercise_price":5.67,"exercise_date":"2022-08-31","expiration_date":"2025-09-30","underlying":"Common  Stock"},"source":{"system":"sec-edgar","filing":"0000950170-23-048020","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000095017023048020/ownership.xml","form_type":"4"}},{"id":1781934,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":4,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Amended and Restated Convertible Promissory Note","published_at":"2023-09-14T01:07:11.000Z","date":"2023-09-11","kind":"other","planned":false,"acquired":false,"price":0,"reported_value":40460274,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC (\"Nant Capital\"), NantMobile, LLC (\"NantMobile\") and NantCancerStemCell, LLC (\"NCSC\" and together with Nant Capital and NantMobile, the \"Purchasers\"), entered into a Stock Purchase Agreement (the \"SPA\") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the \"Notes,\" at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes."},{"field":"reported_value","element":"transactionTotalValue","label":"F10","text":"Represents the entire outstanding principal amount and accrued and unpaid interest due as of September 8, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC (\"Nant Capital\"), NantMobile, LLC (\"NantMobile\") and NantCancerStemCell, LLC (\"NCSC\" and together with Nant Capital and NantMobile, the \"Purchasers\"), entered into a Stock Purchase Agreement (the \"SPA\") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the \"Notes,\" at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"Amended and Restated Convertible Promissory Note held by Nant Capital, an investment vehicle of the reporting person."}],"derivative":{"exercise_price":5.67,"exercise_date":"2022-08-31","expiration_date":"2025-09-30","underlying":"Common  Stock"},"source":{"system":"sec-edgar","filing":"0000950170-23-048020","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000095017023048020/ownership.xml","form_type":"4"}},{"id":1781933,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":4,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-14T01:07:11.000Z","date":"2023-09-11","kind":"other","planned":false,"acquired":true,"shares":32606985,"price":1.29,"value":42063010.65,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC (\"Nant Capital\"), NantMobile, LLC (\"NantMobile\") and NantCancerStemCell, LLC (\"NCSC\" and together with Nant Capital and NantMobile, the \"Purchasers\"), entered into a Stock Purchase Agreement (the \"SPA\") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the \"Notes,\" at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by NCSC. NantBio, Inc. (\"NantBio\") is the sole stockholder and an affiliate of NCSC and may be deemed to have beneficial ownership of the securities held by NCSC. NantWorks is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the securities held by NantBio and its affiliates. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantBio and its affiliates."}],"balance_after":32606985,"source":{"system":"sec-edgar","filing":"0000950170-23-048020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000095017023048020/ownership.xml","form_type":"4"}},{"id":1781932,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":4,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-14T01:07:11.000Z","date":"2023-09-11","kind":"other","planned":false,"acquired":true,"shares":47557934,"price":1.29,"value":61349734.86,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC (\"Nant Capital\"), NantMobile, LLC (\"NantMobile\") and NantCancerStemCell, LLC (\"NCSC\" and together with Nant Capital and NantMobile, the \"Purchasers\"), entered into a Stock Purchase Agreement (the \"SPA\") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the \"Notes,\" at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by NantMobile. NantWorks, LLC (\"NantWorks\") is the majority stockholder and an affiliate of NantMobile and may be deemed to have beneficial ownership of the securities held by NantMobile. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantMobile."}],"balance_after":47557934,"source":{"system":"sec-edgar","filing":"0000950170-23-048020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000095017023048020/ownership.xml","form_type":"4"}},{"id":1781931,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":4,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-14T01:07:11.000Z","date":"2023-09-11","kind":"other","planned":false,"acquired":true,"shares":129127017,"price":1.29,"value":166573851.93,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 11, 2023, the Issuer, the Issuer's wholly-owned subsidiary NantCell, Inc., Nant Capital, LLC (\"Nant Capital\"), NantMobile, LLC (\"NantMobile\") and NantCancerStemCell, LLC (\"NCSC\" and together with Nant Capital and NantMobile, the \"Purchasers\"), entered into a Stock Purchase Agreement (the \"SPA\") pursuant to which the Purchasers exchanged certain existing convertible promissory notes, identified in the SPA as the \"Notes,\" at a price per share of $1.29. As a result of the exchange, the Issuer is forever released and discharged from all its obligations and liabilities under the Notes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Nant Capital, an investment vehicle of the reporting person."}],"balance_after":129227017,"source":{"system":"sec-edgar","filing":"0000950170-23-048020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000095017023048020/ownership.xml","form_type":"4"}},{"id":1786850,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-06T21:12:56.000Z","date":"2023-09-01","kind":"purchase","planned":false,"acquired":true,"shares":7360,"price":6.4934,"value":47791.424,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $6.18 to $7.00. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On August 31, 2023, the issuer effected a 1-for-35 reverse stock split (the \"Reverse Stock Split\") of its outstanding shares of Common Stock. The numbers of shares of Common Stock reported on this Form 4 have been adjusted to reflect the Reverse Split unless otherwise noted."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":946275,"source":{"system":"sec-edgar","filing":"0000899243-23-018664","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323018664/doc4.xml","form_type":"4"}},{"id":1792890,"issuer":{"id":109592,"kind":"organization","name":"NantHealth, Inc.","symbol":"NHIQ"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110097,"kind":"organization","name":"NantWorks, LLC","position":3,"cik":"0001675760","reported_name":"NantWorks, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":4,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-30T17:26:12.000Z","date":"2023-08-28","kind":"purchase","planned":false,"acquired":true,"shares":537272,"price":18.6125,"value":9999975.1,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares of common stock, par value $0.0001 per share (\"Common Stock\"), acquired from the issuer pursuant to a Stock Purchase Agreement (the \"Purchase Agreement\"), dated as of August 28, 2023, by and between the issuer and certain institutional and accredited investors, each as listed as signatories to the Purchase Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"$10,000,000 aggregate principal amount of the demand promissory note, dated January 4, 2016, as amended and restated on May 9, 2016 and April 27, 2021, respectively, by and between the issuer and Nant Capital (the \"Subordinated Nant Capital Promissory Note\"), were exchanged for shares of Common Stock in accordance with the terms and conditions of the Subordinated Nant Capital Promissory Note."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Nant Capital, LLC (\"Nant Capital\"). California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and CalCap may be deemed to have beneficial ownership of the shares held by Nant Capital. Patrick Soon-Shiong directly owns all of the equity interests of CalCap and has voting and dispositive power over the shares held by CalCap."}],"balance_after":15921888,"source":{"system":"sec-edgar","filing":"0000950170-23-045521","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000095017023045521/ownership.xml","form_type":"4"}},{"id":1792889,"issuer":{"id":109592,"kind":"organization","name":"NantHealth, Inc.","symbol":"NHIQ"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110097,"kind":"organization","name":"NantWorks, LLC","position":3,"cik":"0001675760","reported_name":"NantWorks, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":4,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-30T17:26:12.000Z","date":"2023-08-28","kind":"purchase","planned":false,"acquired":true,"shares":15384616,"price":0.39,"value":6000000.24,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares of common stock, par value $0.0001 per share (\"Common Stock\"), acquired from the issuer pursuant to a Stock Purchase Agreement (the \"Purchase Agreement\"), dated as of August 28, 2023, by and between the issuer and certain institutional and accredited investors, each as listed as signatories to the Purchase Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Nant Capital, LLC (\"Nant Capital\"). California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and CalCap may be deemed to have beneficial ownership of the shares held by Nant Capital. Patrick Soon-Shiong directly owns all of the equity interests of CalCap and has voting and dispositive power over the shares held by CalCap."}],"balance_after":15384616,"source":{"system":"sec-edgar","filing":"0000950170-23-045521","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000095017023045521/ownership.xml","form_type":"4"}},{"id":1844084,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-26T21:51:44.000Z","date":"2023-06-22","kind":"purchase","planned":false,"acquired":true,"shares":634251,"price":0.2303,"value":146068.0053,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $0.23 to $0.24. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":32862027,"source":{"system":"sec-edgar","filing":"0000899243-23-016529","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323016529/doc4.xml","form_type":"4"}},{"id":1847637,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-21T18:16:00.000Z","date":"2023-06-21","kind":"purchase","planned":false,"acquired":true,"shares":263695,"price":0.2346,"value":61862.847,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $0.2304 to $0.2350. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":32227776,"source":{"system":"sec-edgar","filing":"0000899243-23-016170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323016170/doc4.xml","form_type":"4"}},{"id":1847636,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-21T18:16:00.000Z","date":"2023-06-20","kind":"purchase","planned":false,"acquired":true,"shares":62916,"price":0.234,"value":14722.344,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $0.2327 to $0.2350. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":31964081,"source":{"system":"sec-edgar","filing":"0000899243-23-016170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323016170/doc4.xml","form_type":"4"}},{"id":1847635,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-21T18:16:00.000Z","date":"2023-06-16","kind":"purchase","planned":false,"acquired":true,"shares":40048,"price":0.2198,"value":8802.5504,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $0.2161 to $0.2200. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":31901165,"source":{"system":"sec-edgar","filing":"0000899243-23-016170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323016170/doc4.xml","form_type":"4"}},{"id":1854074,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-15T19:31:03.000Z","date":"2023-06-15","kind":"purchase","planned":false,"acquired":true,"shares":387612,"price":0.2096,"value":81243.4752,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $0.2085 to $0.2100. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":31861117,"source":{"system":"sec-edgar","filing":"0000899243-23-015652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323015652/doc4.xml","form_type":"4"}},{"id":1854073,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-15T19:31:03.000Z","date":"2023-06-14","kind":"purchase","planned":false,"acquired":true,"shares":279752,"price":0.21,"value":58747.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $0.2090 to $0.2100. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":31473505,"source":{"system":"sec-edgar","filing":"0000899243-23-015652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323015652/doc4.xml","form_type":"4"}},{"id":1854072,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-15T19:31:03.000Z","date":"2023-06-13","kind":"purchase","planned":false,"acquired":true,"shares":1058542,"price":0.199,"value":210649.858,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $0.1912 to $0.2000. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":31193753,"source":{"system":"sec-edgar","filing":"0000899243-23-015652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323015652/doc4.xml","form_type":"4"}},{"id":1860293,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T19:45:29.000Z","date":"2023-06-09","kind":"purchase","planned":false,"acquired":true,"shares":768835,"price":0.2299,"value":176755.1665,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $0.2298 to $0.23. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":30135211,"source":{"system":"sec-edgar","filing":"0000899243-23-015295","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323015295/doc4.xml","form_type":"4"}},{"id":1860292,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T19:45:29.000Z","date":"2023-06-08","kind":"purchase","planned":false,"acquired":true,"shares":1966263,"price":0.2188,"value":430218.3444,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $0.214 to $0.23. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":29366376,"source":{"system":"sec-edgar","filing":"0000899243-23-015295","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323015295/doc4.xml","form_type":"4"}},{"id":1860291,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T19:45:29.000Z","date":"2023-06-07","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"price":0.2452,"value":245200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $0.2437 to $0.2485. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":27400113,"source":{"system":"sec-edgar","filing":"0000899243-23-015295","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323015295/doc4.xml","form_type":"4"}},{"id":1866585,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T19:21:30.000Z","date":"2023-06-02","kind":"purchase","planned":false,"acquired":true,"shares":158355,"price":0.2447,"value":38749.4685,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $0.2328 to $0.25. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":26400113,"source":{"system":"sec-edgar","filing":"0000899243-23-014517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323014517/doc4.xml","form_type":"4"}},{"id":1866584,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T19:21:30.000Z","date":"2023-06-01","kind":"purchase","planned":false,"acquired":true,"shares":21657,"price":0.2498,"value":5409.9186,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $0.2472 to $0.25. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":26241758,"source":{"system":"sec-edgar","filing":"0000899243-23-014517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323014517/doc4.xml","form_type":"4"}},{"id":1891329,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}}],"security":"Convertible Promissory Note","published_at":"2023-05-17T00:30:36.000Z","date":"2023-05-12","kind":"purchase","planned":false,"acquired":true,"price":30445859,"reported_value":30455859,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F1","text":"On May 12, 2023, the conversion price of the convertible promissory note previously issued on March 31, 2023 was fixed at $2.28 per share and the lender has the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under such note at the time of conversion into shares of the Issuer's common stock at a price of $2.28 per share. Dollar amount shown reflects the aggregate principal and interest accrued as of May 12, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Convertible Promissory Note held by Nant Capital, LLC, an investment vehicle of the reporting person."}],"derivative":{"exercise_price":2.28,"exercise_date":"2023-05-12","expiration_date":"2023-12-31","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001326110-23-000066","document":"wf-form4_168428341644684.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611023000066/wf-form4_168428341644684.xml","form_type":"4"}},{"id":1918894,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-17T17:18:47.000Z","date":"2023-04-13","kind":"purchase","planned":false,"acquired":true,"shares":7077,"price":0.25,"value":1769.25,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":26220101,"source":{"system":"sec-edgar","filing":"0000899243-23-011312","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323011312/doc4.xml","form_type":"4"}},{"id":1920836,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-12T20:06:47.000Z","date":"2023-04-12","kind":"purchase","planned":false,"acquired":true,"shares":172345,"price":0.2496,"value":43017.312,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $0.2469 to $0.25. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":26213024,"source":{"system":"sec-edgar","filing":"0000899243-23-011223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323011223/doc4.xml","form_type":"4"}},{"id":1920835,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-12T20:06:47.000Z","date":"2023-04-11","kind":"purchase","planned":false,"acquired":true,"shares":280219,"price":0.25,"value":70054.75,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":26040679,"source":{"system":"sec-edgar","filing":"0000899243-23-011223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323011223/doc4.xml","form_type":"4"}},{"id":1920834,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-12T20:06:47.000Z","date":"2023-04-10","kind":"purchase","planned":false,"acquired":true,"shares":88086,"price":0.2494,"value":21968.6484,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $0.2463 to $0.25. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":25760460,"source":{"system":"sec-edgar","filing":"0000899243-23-011223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323011223/doc4.xml","form_type":"4"}},{"id":1922229,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-10T21:21:18.000Z","date":"2023-04-06","kind":"purchase","planned":false,"acquired":true,"shares":641027,"price":0.2482,"value":159102.9014,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $0.2424 to $0.25. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":25672374,"source":{"system":"sec-edgar","filing":"0000899243-23-011075","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323011075/doc4.xml","form_type":"4"}},{"id":1922228,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-10T21:21:18.000Z","date":"2023-04-05","kind":"purchase","planned":false,"acquired":true,"shares":385024,"price":0.2446,"value":94176.8704,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $0.2312 to $0.25. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":25031347,"source":{"system":"sec-edgar","filing":"0000899243-23-011075","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323011075/doc4.xml","form_type":"4"}},{"id":1937785,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-27T18:55:55.000Z","date":"2023-03-24","kind":"purchase","planned":false,"acquired":true,"shares":907677,"price":0.2387,"value":216662.4999,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $0.2136 to $0.2500. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are solely owned by Dr. Patrick Soon-Shiong, who is a member of a \"group\" with Nant Capital for purposes of Section 13(d) of the Exchange Act."}],"balance_after":2345714,"source":{"system":"sec-edgar","filing":"0000899243-23-009756","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323009756/doc4.xml","form_type":"4"}},{"id":1937784,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-27T18:55:55.000Z","date":"2023-03-23","kind":"purchase","planned":false,"acquired":true,"shares":426374,"price":0.21,"value":89538.54,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $0.2079 to $0.2100. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are solely owned by Dr. Patrick Soon-Shiong, who is a member of a \"group\" with Nant Capital for purposes of Section 13(d) of the Exchange Act."}],"balance_after":1438037,"source":{"system":"sec-edgar","filing":"0000899243-23-009756","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924323009756/doc4.xml","form_type":"4"}},{"id":2086356,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":4,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Second Amended and Restated Convertible Promissory Note","published_at":"2022-12-14T21:23:52.000Z","date":"2022-12-12","kind":"exercise","acquired":false,"price":0,"reported_value":56625841.51,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"On August 31, 2022, the terms of the original fixed-rate promissory note were amended and restated to include a conversion feature that gave the lender the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under the note at the time of conversion into shares of the Issuer's common stock at a price of $5.67 per share.  On December 12, 2022, the lender converted $56,625,841.51 in outstanding principal and accrued unpaid interest into 9,986,920 shares of the Issuer's common stock at a price of $5.67 per share."},{"field":"reported_value","element":"transactionTotalValue","label":"F8","text":"Represents the entire outstanding principal amount and accrued and unpaid interest due as of December 12, 2022."},{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F7","text":"On August 31, 2022, the terms of the original fixed-rate promissory note were amended and restated to include a conversion feature that gave the lender the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under the note at the time of conversion into shares of the Issuer's common stock at a price of $5.67 per share.  On December 12, 2022, the lender converted $56,625,841.51 in outstanding principal and accrued unpaid interest into 9,986,920 shares of the Issuer's common stock at a price of $5.67 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Second Amended and Restated Convertible Promissory Note held by NantWorks. CalCap directly owns all of the equity interests of NantWorks and may be deemed to have beneficial ownership of the securities held by NantWorks. The reporting person directly owns all of the equity interests of CalCap and may be deemed to have voting and dispositive power over the securities held by NantWorks."}],"derivative":{"exercise_price":5.67,"exercise_date":"2022-08-31","expiration_date":"2025-09-30","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001326110-22-000089","document":"wf-form4_167105301713045.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611022000089/wf-form4_167105301713045.xml","form_type":"4"}},{"id":2086355,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":4,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-14T21:23:52.000Z","date":"2022-12-12","kind":"exercise","acquired":true,"shares":9986920,"price":5.67,"value":56625836.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by NantWorks, LLC (\"NantWorks\"). California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of NantWorks and may be deemed to have beneficial ownership of the securities held by NantWorks. The reporting person directly owns all of the equity interests of CalCap and may be deemed to have voting and dispositive power over the securities held by NantWorks."}],"balance_after":9986920,"source":{"system":"sec-edgar","filing":"0001326110-22-000089","document":"wf-form4_167105301713045.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611022000089/wf-form4_167105301713045.xml","form_type":"4"}},{"id":2122140,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}}],"security":"Second Amended and Restated Convertible Promissory Note","published_at":"2022-11-08T21:01:23.000Z","date":"2022-08-31","kind":"purchase","acquired":true,"price":40016261,"reported_value":40016261,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 31, 2022, the terms of the original fixed-rate promissory note were amended and restated to include a conversion feature that gives each lender the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the Issuer's common stock at a price of $5.67  per share.  Dollar amounts shown reflect the aggregate principal and interest accrued as of August 31. 2022."},{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F1","text":"On August 31, 2022, the terms of the original fixed-rate promissory note were amended and restated to include a conversion feature that gives each lender the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the Issuer's common stock at a price of $5.67  per share.  Dollar amounts shown reflect the aggregate principal and interest accrued as of August 31. 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Second Amended and Restated Convertible Promissory Note held by NantCancerStemCell, LLC (\"NantCancerStemCell\"). NantBio, Inc. (\"NantBio\") is the majority stockholder and an affiliate of NantCancerStemCell and may be deemed to have beneficial ownership of the securities held by NantCancerStemCell.  NantWorks, LLC (\"NantWorks\") is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the securities held by NantBio and its affiliates. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantBio and its affiliates."}],"derivative":{"exercise_price":5.67,"exercise_date":"2022-08-31","expiration_date":"2025-09-30","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001326110-22-000070","document":"wf-form4_166794126693201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611022000070/wf-form4_166794126693201.xml","form_type":"4"}},{"id":2122139,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}}],"security":"Second Amended and Restated Convertible Promissory Note","published_at":"2022-11-08T21:01:23.000Z","date":"2022-08-31","kind":"purchase","acquired":true,"price":59524425,"reported_value":59524425,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 31, 2022, the terms of the original fixed-rate promissory note were amended and restated to include a conversion feature that gives each lender the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the Issuer's common stock at a price of $5.67  per share.  Dollar amounts shown reflect the aggregate principal and interest accrued as of August 31. 2022."},{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F1","text":"On August 31, 2022, the terms of the original fixed-rate promissory note were amended and restated to include a conversion feature that gives each lender the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the Issuer's common stock at a price of $5.67  per share.  Dollar amounts shown reflect the aggregate principal and interest accrued as of August 31. 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Second Amended and Restated Convertible Promissory Note held by NantMobile, LLC (\"NantMobile\"). NantWorks, LLC (\"NantWorks\") is the majority stockholder and an affiliate of NantMobile and may be deemed to have beneficial ownership of the securities held by NantMobile. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantMobile."}],"derivative":{"exercise_price":5.67,"exercise_date":"2022-08-31","expiration_date":"2025-09-30","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001326110-22-000070","document":"wf-form4_166794126693201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611022000070/wf-form4_166794126693201.xml","form_type":"4"}},{"id":2122138,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}}],"security":"Second Amended and Restated Convertible Promissory Note","published_at":"2022-11-08T21:01:23.000Z","date":"2022-08-31","kind":"purchase","acquired":true,"price":55844638,"reported_value":55844638,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 31, 2022, the terms of the original fixed-rate promissory note were amended and restated to include a conversion feature that gives each lender the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the Issuer's common stock at a price of $5.67  per share.  Dollar amounts shown reflect the aggregate principal and interest accrued as of August 31. 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On August 31, 2022, the terms of the original fixed-rate promissory note were amended and restated to include a conversion feature that gives each lender the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the Issuer's common stock at a price of $5.67  per share.  Dollar amounts shown reflect the aggregate principal and interest accrued as of August 31. 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Second Amended and Restated Convertible Promissory Note held by NantWorks, LLC (\"NantWorks\"). California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of NantWorks and may be deemed to have beneficial ownership of the securities held by NantWorks. The reporting person directly owns all of the equity interests of CalCap and may be deemed to have voting and dispositive power over the securities held by NantWorks."}],"derivative":{"exercise_price":5.67,"exercise_date":"2022-08-31","expiration_date":"2025-09-30","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001326110-22-000070","document":"wf-form4_166794126693201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611022000070/wf-form4_166794126693201.xml","form_type":"4"}},{"id":2122137,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}}],"security":"Second Amended and Restated Convertible Promissory Note","published_at":"2022-11-08T21:01:23.000Z","date":"2022-08-31","kind":"purchase","acquired":true,"price":63375911,"reported_value":63375911,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 31, 2022, the terms of the original fixed-rate promissory note were amended and restated to include a conversion feature that gives each lender the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the Issuer's common stock at a price of $5.67  per share.  Dollar amounts shown reflect the aggregate principal and interest accrued as of August 31. 2022."},{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F1","text":"On August 31, 2022, the terms of the original fixed-rate promissory note were amended and restated to include a conversion feature that gives each lender the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the Issuer's common stock at a price of $5.67  per share.  Dollar amounts shown reflect the aggregate principal and interest accrued as of August 31. 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Second Amended and Restated Convertible Promissory Note held by NantCapital, LLC, an investment vehicle of the reporting person."}],"derivative":{"exercise_price":5.67,"exercise_date":"2022-08-31","expiration_date":"2025-09-30","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001326110-22-000070","document":"wf-form4_166794126693201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611022000070/wf-form4_166794126693201.xml","form_type":"4"}},{"id":2122136,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}}],"security":"Amended and Restated Convertible Promissory Note","published_at":"2022-11-08T21:01:23.000Z","date":"2022-08-31","kind":"purchase","acquired":true,"price":55927342,"reported_value":55927342,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 31, 2022, the terms of the original fixed-rate promissory note were amended and restated to include a conversion feature that gives each lender the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the Issuer's common stock at a price of $5.67  per share.  Dollar amounts shown reflect the aggregate principal and interest accrued as of August 31. 2022."},{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F1","text":"On August 31, 2022, the terms of the original fixed-rate promissory note were amended and restated to include a conversion feature that gives each lender the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the Issuer's common stock at a price of $5.67  per share.  Dollar amounts shown reflect the aggregate principal and interest accrued as of August 31. 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Amended and Restated Convertible Promissory Note held by NantCapital, LLC, an investment vehicle of the reporting person."}],"derivative":{"exercise_price":5.67,"exercise_date":"2022-08-31","expiration_date":"2025-09-30","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001326110-22-000070","document":"wf-form4_166794126693201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611022000070/wf-form4_166794126693201.xml","form_type":"4"}},{"id":2122135,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}}],"security":"Amended and Restated Convertible Promissory Note","published_at":"2022-11-08T21:01:23.000Z","date":"2022-08-31","kind":"purchase","acquired":true,"price":40407671,"reported_value":40407671,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 31, 2022, the terms of the original fixed-rate promissory note were amended and restated to include a conversion feature that gives each lender the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the Issuer's common stock at a price of $5.67  per share.  Dollar amounts shown reflect the aggregate principal and interest accrued as of August 31. 2022."},{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F1","text":"On August 31, 2022, the terms of the original fixed-rate promissory note were amended and restated to include a conversion feature that gives each lender the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the Issuer's common stock at a price of $5.67  per share.  Dollar amounts shown reflect the aggregate principal and interest accrued as of August 31. 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Amended and Restated Convertible Promissory Note held by NantCapital, LLC, an investment vehicle of the reporting person."}],"derivative":{"exercise_price":5.67,"exercise_date":"2022-08-31","expiration_date":"2025-09-30","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001326110-22-000070","document":"wf-form4_166794126693201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611022000070/wf-form4_166794126693201.xml","form_type":"4"}},{"id":2214223,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-05T16:47:06.000Z","date":"2021-12-30","kind":"grant","acquired":true,"shares":1011663,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Received on December 30, 2021 pursuant to that certain Business Combination Agreement, dated as of July 6, 2021, by and among Athena Technology Acquisition Corp., a Delaware corporation (\"Athena\"), HelioMax Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Athena, and Heliogen, Inc., a Delaware corporation (\"Legacy Heliogen\"), in exchange for Legacy Heliogen shares."},{"field":"shares","element":"transactionShares","label":"F3","text":"These shares are solely owned by Dr. Patrick Soon-Shiong, who is a member of a \"group\" with Nant Capital for purposes of Section 13(d) of the Exchange Act."}],"balance_after":1011663,"source":{"system":"sec-edgar","filing":"0000899243-22-025001","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924322025001/doc4.xml","form_type":"4"}},{"id":2214222,"issuer":{"id":78373,"kind":"organization","name":"Heliogen, Inc.","symbol":"HLGN"},"owners":[{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":1,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":3,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-05T16:47:06.000Z","date":"2021-12-30","kind":"grant","acquired":true,"shares":24646323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Received on December 30, 2021 pursuant to that certain Business Combination Agreement, dated as of July 6, 2021, by and among Athena Technology Acquisition Corp., a Delaware corporation (\"Athena\"), HelioMax Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Athena, and Heliogen, Inc., a Delaware corporation (\"Legacy Heliogen\"), in exchange for Legacy Heliogen shares."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are owned by Nant Capital LLC (\"Nant Capital\"), who is a member of a \"group\" with Dr. Patrick Soon-Shiong for purposes of Section 13(d) of the Exchange Act. Additionally, California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital and Dr. Soon-Shiong directly owns all of the equity interests of CalCap. As a result, CalCap and Dr. Soon-Shiong may be deemed to beneficially own, and share with Nant Capital the power to vote and  direct the vote, and the power to dispose or direct the disposition of, the shares beneficially owned by Nant Capital."}],"balance_after":24646323,"source":{"system":"sec-edgar","filing":"0000899243-22-025001","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924322025001/doc4.xml","form_type":"4"}},{"id":2317614,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-26T01:05:02.000Z","date":"2022-03-23","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Issuer's attainment of a financial goal for fiscal year 2022, one-third (1/3rd) of the shares subject to the option shall vest in equal annual installments on each of the first, second and third anniversaries of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date, subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date. The vesting commencement date for this option is March 23, 2022."}],"balance_after":350000,"derivative":{"exercise_price":5.83,"expiration_date":"2032-03-23","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001326110-22-000020","document":"wf-form4_164825668605011.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611022000020/wf-form4_164825668605011.xml","form_type":"4"}},{"id":2317613,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-26T01:05:02.000Z","date":"2022-03-23","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option shall vest in equal annual installments on each of the first, second and third anniversaries of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is March 23, 2022."}],"balance_after":350000,"derivative":{"exercise_price":5.83,"expiration_date":"2032-03-23","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001326110-22-000020","document":"wf-form4_164825668605011.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611022000020/wf-form4_164825668605011.xml","form_type":"4"}},{"id":2571850,"issuer":{"id":109592,"kind":"organization","name":"NantHealth, Inc.","symbol":"NHIQ"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-13T20:19:01.000Z","date":"2021-09-09","kind":"grant","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person continuing as a service provider, the shares subject to the option shall vest as follows, fifty percent (50%) of the shares subject to the option shall vest on the one (1) year anniversary from the date of grant, and twenty-five percent (25%) of the remaining shares subject to the option shall vest annually thereafter, so that the option is fully vested on the three (3) year anniversary date."}],"balance_after":1000000,"derivative":{"exercise_price":1.96,"expiration_date":"2031-09-09","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-21-035741","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924321035741/doc4.xml","form_type":"4"}},{"id":2669970,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-14T22:38:03.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":26064,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 10, 2022 or the date immediately preceding the 2022 annual meeting of stockholders."}],"balance_after":26064,"derivative":{"exercise_price":14.91,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":26064},"source":{"system":"sec-edgar","filing":"0001209191-21-040356","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120919121040356/doc4.xml","form_type":"4"}},{"id":2737063,"issuer":{"id":109592,"kind":"organization","name":"NantHealth, Inc.","symbol":"NHIQ"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman and CEO"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":3,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"4.50% Convertible Senior Notes due 2026","published_at":"2021-04-28T18:54:28.000Z","date":"2021-04-27","kind":"purchase","acquired":true,"shares":62500000,"price":62500000,"value":3.90625e+15,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The initial conversion rate of the 4.50% Convertible Senior Notes due 2026 (the \"Notes\") is 259.8753 shares of common stock per $1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately $3.85 per share), subject to adjustment pursuant to the terms of the Notes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Notes will be convertible at the option of the reporting persons at any time prior to the close of business on the business day immediately preceding the maturity date of the Notes.  The Notes will be convertible into cash, shares of the issuer's common stock, or a combination thereof, at the issuer's election"},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The initial conversion rate of the 4.50% Convertible Senior Notes due 2026 (the \"Notes\") is 259.8753 shares of common stock per $1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately $3.85 per share), subject to adjustment pursuant to the terms of the Notes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Notes are held by Nant Capital LLC (\"Nant Capital\"). California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of Nant Capital, LLC and CalCap may be deemed to have beneficial ownership of the shares held by Nant Capital. Patrick Soon-Shiong directly owns all of the equity interests of CalCap and has voting and dispositive power over the shares held by CalCap."}],"derivative":{"expiration_date":"2026-04-27","underlying":"Common Stock","underlying_shares":16242206},"source":{"system":"sec-edgar","filing":"0000899243-21-017244","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924321017244/doc4.xml","form_type":"4"}},{"id":2748430,"issuer":{"id":109592,"kind":"organization","name":"NantHealth, Inc.","symbol":"NHIQ"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110097,"kind":"organization","name":"NantWorks, LLC","position":3,"cik":"0001675760","reported_name":"NantWorks, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":4,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":5,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5.50% Convertible Senior Notes due 2021","published_at":"2021-04-15T18:04:34.000Z","date":"2021-04-13","kind":"other","acquired":false,"shares":5000000,"price":5000000,"value":25000000000000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The initial conversion rate of the 5.50% Convertible Senior Notes due 2021 (the \"Notes\") is 82.3893 shares of common stock per $1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately $12.14 per share), subject to adjustment pursuant to the terms of the Notes."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Portion of the Convertible Senior Note was forgiven as consideration for the purchase of shares reported in Table I."},{"field":"shares","element":"transactionShares","label":"F5","text":"Portion of the Convertible Senior Note was forgiven as consideration for the purchase of shares reported in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Notes will be convertible at the option of the reporting persons only upon the satisfaction of certain conditions prior to the close of business on the business day immediately preceding September 15, 2021. Thereafter, the Notes will be convertible at the option of the reporting persons at any time or after September 15, 2021 until the close of business on the business day immediately preceding the maturity date. The Notes will be convertible into cash, shares of the issuer's common stock, or a combination thereof, at the issuer's election."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The initial conversion rate of the 5.50% Convertible Senior Notes due 2021 (the \"Notes\") is 82.3893 shares of common stock per $1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately $12.14 per share), subject to adjustment pursuant to the terms of the Notes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The Notes are held by Cambridge Equities, an entity affiliated with MP 13 Ventures, LLC who is the general partner of Cambridge Equities and may be deemed to have beneficial ownership of the convertible notes held by Cambridge Equities. The reporting person is the sole member of MP 13 Ventures and has voting and dispositive power over the convertible notes held by Cambridge Equities."}],"balance_after":5000000,"derivative":{"expiration_date":"2021-12-15","underlying":"Common Stock","underlying_shares":411946},"source":{"system":"sec-edgar","filing":"0000899243-21-015976","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924321015976/doc4.xml","form_type":"4"}},{"id":2748429,"issuer":{"id":109592,"kind":"organization","name":"NantHealth, Inc.","symbol":"NHIQ"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110097,"kind":"organization","name":"NantWorks, LLC","position":3,"cik":"0001675760","reported_name":"NantWorks, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":4,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":5,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T18:04:34.000Z","date":"2021-04-13","kind":"purchase","acquired":true,"shares":1689189,"price":2.96,"value":4999999.44,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by Cambridge Equities, LP (\"Cambridge Equities\"), an entity affiliated with MP 13 Ventures, LLC (\"MP 13 Ventures\") who is the general partner of Cambridge Equities. The reporting person is the sole member of MP 13 Ventures and has voting and dispositive power over the shares held by Cambridge Equities."}],"balance_after":1689189,"source":{"system":"sec-edgar","filing":"0000899243-21-015976","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924321015976/doc4.xml","form_type":"4"}},{"id":2794378,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-12T02:30:53.000Z","date":"2021-03-09","kind":"other","acquired":true,"shares":7976159,"ownership":{"direct":false,"nature":"See footnte"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the terms and subject to the conditions set forth in the Agreement and Plan of Merger, dated as of December 21, 2020, by and among NantKwest. Inc. (\"NantKwest\"), Nectarine Merger Sub, Inc., a wholly owned subsidiary of NantKwest (\"Merger Sub\"), and ImmunityBio, Inc. (\"ImmunityBio\"), Merger Sub merged with and into ImmunityBio, with ImmunityBio surviving as a wholly owned subsidiary of NantKwest and was renamed NantCell, Inc. Following the completion of the merger, NantKwest was renamed ImmunityBio, Inc. In the merger, NantKwest issued to the stockholders of ImmunityBio 0.8190 of a share of its common stock, par value $0.0001 per share, for each outstanding share of ImmunityBio common stock, and the derivative securities of ImmunityBio were also correspondingly converted to derivatives of NantKwest at the same ratio."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by California Capital Equity, LLC (\"CalCap\").  The reporting person owns all of the equity interests of CalCap and has voting and dispositive power over the shares held by CalCap."}],"balance_after":7976159,"source":{"system":"sec-edgar","filing":"0001209191-21-020020","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120919121020020/doc4.xml","form_type":"4"}},{"id":2794377,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-12T02:30:53.000Z","date":"2021-03-09","kind":"other","acquired":true,"shares":8383414,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the terms and subject to the conditions set forth in the Agreement and Plan of Merger, dated as of December 21, 2020, by and among NantKwest. Inc. (\"NantKwest\"), Nectarine Merger Sub, Inc., a wholly owned subsidiary of NantKwest (\"Merger Sub\"), and ImmunityBio, Inc. (\"ImmunityBio\"), Merger Sub merged with and into ImmunityBio, with ImmunityBio surviving as a wholly owned subsidiary of NantKwest and was renamed NantCell, Inc. Following the completion of the merger, NantKwest was renamed ImmunityBio, Inc. In the merger, NantKwest issued to the stockholders of ImmunityBio 0.8190 of a share of its common stock, par value $0.0001 per share, for each outstanding share of ImmunityBio common stock, and the derivative securities of ImmunityBio were also correspondingly converted to derivatives of NantKwest at the same ratio."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by NantBio, Inc. (\"NantBio\").  NantWorks, LLC (\"NantWorks\") is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the shares held by NantBio. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the shares held by NantBio."}],"balance_after":8383414,"source":{"system":"sec-edgar","filing":"0001209191-21-020020","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120919121020020/doc4.xml","form_type":"4"}},{"id":2794376,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-12T02:30:53.000Z","date":"2021-03-09","kind":"other","acquired":true,"shares":221130000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the terms and subject to the conditions set forth in the Agreement and Plan of Merger, dated as of December 21, 2020, by and among NantKwest. Inc. (\"NantKwest\"), Nectarine Merger Sub, Inc., a wholly owned subsidiary of NantKwest (\"Merger Sub\"), and ImmunityBio, Inc. (\"ImmunityBio\"), Merger Sub merged with and into ImmunityBio, with ImmunityBio surviving as a wholly owned subsidiary of NantKwest and was renamed NantCell, Inc. Following the completion of the merger, NantKwest was renamed ImmunityBio, Inc. In the merger, NantKwest issued to the stockholders of ImmunityBio 0.8190 of a share of its common stock, par value $0.0001 per share, for each outstanding share of ImmunityBio common stock, and the derivative securities of ImmunityBio were also correspondingly converted to derivatives of NantKwest at the same ratio."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Cambridge Equities, LP (\"Cambridge Equities\"). MP 13 Ventures, LLC (\"MP 13 Ventures\") is the general partner of Cambridge Equities and may be deemed to have beneficial ownership of the shares held by Cambridge Equities. The reporting person is the sole member of MP 13 Ventures and has voting and dispositive power over the shares held by Cambridge Equities."}],"balance_after":261705814,"source":{"system":"sec-edgar","filing":"0001209191-21-020020","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120919121020020/doc4.xml","form_type":"4"}},{"id":2794375,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-12T02:30:53.000Z","date":"2021-03-09","kind":"other","acquired":true,"shares":5723182,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the terms and subject to the conditions set forth in the Agreement and Plan of Merger, dated as of December 21, 2020, by and among NantKwest. Inc. (\"NantKwest\"), Nectarine Merger Sub, Inc., a wholly owned subsidiary of NantKwest (\"Merger Sub\"), and ImmunityBio, Inc. (\"ImmunityBio\"), Merger Sub merged with and into ImmunityBio, with ImmunityBio surviving as a wholly owned subsidiary of NantKwest and was renamed NantCell, Inc. Following the completion of the merger, NantKwest was renamed ImmunityBio, Inc. In the merger, NantKwest issued to the stockholders of ImmunityBio 0.8190 of a share of its common stock, par value $0.0001 per share, for each outstanding share of ImmunityBio common stock, and the derivative securities of ImmunityBio were also correspondingly converted to derivatives of NantKwest at the same ratio."}],"balance_after":29473932,"source":{"system":"sec-edgar","filing":"0001209191-21-020020","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120919121020020/doc4.xml","form_type":"4"}},{"id":3097469,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman and CEO"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-29T23:36:25.000Z","date":"2020-06-29","kind":"purchase","acquired":true,"shares":3710000,"price":12.12,"value":44965200.0,"ownership":{"direct":true},"balance_after":23750750,"source":{"system":"sec-edgar","filing":"0001209191-20-039238","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120919120039238/doc4.xml","form_type":"4"}},{"id":3376187,"issuer":{"id":109592,"kind":"organization","name":"NantHealth, Inc.","symbol":"NHIQ"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110097,"kind":"organization","name":"NantWorks, LLC","position":3,"cik":"0001675760","reported_name":"NantWorks, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-08T09:00:24.000Z","date":"2019-11-06","kind":"gift","acquired":false,"shares":5000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares transferred for no value by NantWorks, LLC (\"NantWorks\") to (i) MIMI TRUST I OF DE 2009; (ii) STEVE TRUST I OF DE 2009; (iii) MIMI TRUST II OF DE 2009; and (iv) STEVE TRUST II OF DE 2009 (each a \"Grantee\"). Each Grantee received a total of 1,250,000 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by NantWorks. California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of NantWorks and may be deemed to have beneficial ownership of the shares held by NantWorks. The reporting person directly owns all of the equity interests of CalCap and has voting and dispositive power over the shares held by CalCap."}],"balance_after":62214114,"source":{"system":"sec-edgar","filing":"0000899243-19-026921","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924319026921/doc4.xml","form_type":"4"}},{"id":3582817,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman and CEO"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-03-22T01:06:40.000Z","date":"2019-03-21","kind":"exercise","acquired":false,"shares":1851500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Subject to the reporting person's continuing service, one forty-eighth (1/48th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the fourth (4th) anniversary of the vesting commencement date. The vesting commencement date for this option is March 24, 2015. The shares subject to the option shall fully vest and become exercisable upon a change in control, as defined in the reporting person's employment agreement. If the reporting person's employment is terminated without \"cause\" or if the reporting person resigns for \"good reason\" (as such terms are defined in the reporting person's employment agreement), the shares subject to the option shall fully vest and become exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.1983,"expiration_date":"2019-03-24","underlying":"Common Stock","underlying_shares":1851500},"source":{"system":"sec-edgar","filing":"0001209191-19-020891","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120919119020891/doc4.xml","form_type":"4"}},{"id":3582816,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman and CEO"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2019-03-22T01:06:40.000Z","date":"2019-03-21","kind":"other","acquired":false,"shares":17589250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"185,150 of the shares subject to the warrant vested and became exercisable monthly for forty (40) months beginning April 1, 2015. The remaining 10,183,250 shares subject to the warrant vested and became exercisable upon the completion of certain milestones as defined in the warrant."}],"balance_after":0,"derivative":{"exercise_price":1.9984,"expiration_date":"2019-03-24","underlying":"Common Stock","underlying_shares":17589250},"source":{"system":"sec-edgar","filing":"0001209191-19-020891","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120919119020891/doc4.xml","form_type":"4"}},{"id":3582815,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman and CEO"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-03-22T01:06:40.000Z","date":"2019-03-21","kind":"exercise","acquired":true,"shares":1851500,"price":2.1983,"value":4070152.45,"ownership":{"direct":true},"balance_after":20040750,"source":{"system":"sec-edgar","filing":"0001209191-19-020891","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120919119020891/doc4.xml","form_type":"4"}},{"id":3582814,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman and CEO"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-03-22T01:06:40.000Z","date":"2019-03-21","kind":"other","acquired":true,"shares":17589250,"price":1.9984,"value":35150357.2,"ownership":{"direct":true},"balance_after":18189250,"source":{"system":"sec-edgar","filing":"0001209191-19-020891","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120919119020891/doc4.xml","form_type":"4"}},{"id":3867933,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman and CEO"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2018-07-13T23:26:08.000Z","date":"2018-07-11","kind":"exercise","acquired":false,"shares":9257,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Warrant was exercisable on the original date of issuance."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Warrant held by Cambridge Equities, LP (\"Cambridge Equities\"). MP 13 Ventures, LLC (\"MP 13 Ventures\") is the general partner of Cambridge Equities and may be deemed to have beneficial ownership of the warrant and the shares issued upon the exercise of the warrant held by Cambridge Equities. The reporting person is the sole member of MP 13 Ventures and has voting and dispositive power over the warrant and the shares issued upon the exercise of the warrant held by Cambridge Equities."}],"balance_after":0,"derivative":{"exercise_price":1.6204,"expiration_date":"2018-07-27","underlying":"Common Stock","underlying_shares":9257},"source":{"system":"sec-edgar","filing":"0001209191-18-042582","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120919118042582/doc4.xml","form_type":"4"}},{"id":3867932,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman and CEO"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-13T23:26:08.000Z","date":"2018-07-11","kind":"exercise","acquired":true,"shares":9257,"price":1.6204,"value":15000.0428,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Cambridge Equities, LP (\"Cambridge Equities\"). MP 13 Ventures, LLC (\"MP 13 Ventures\") is the general partner of Cambridge Equities and may be deemed to have beneficial ownership of the shares held by Cambridge Equities. The reporting person is the sole member of MP 13 Ventures and has voting and dispositive power over the shares held by Cambridge Equities."}],"balance_after":40565814,"source":{"system":"sec-edgar","filing":"0001209191-18-042582","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120919118042582/doc4.xml","form_type":"4"}},{"id":4376282,"issuer":{"id":138878,"kind":"organization","name":"Tribune Publishing Co","symbol":"TPCO"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-03-21T16:21:35.000Z","date":"2017-03-20","kind":"purchase","acquired":true,"shares":2950000,"price":14.8712,"value":43870040.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price reflects the weighted average purchase price per share for the transactions on March 20, 2017. The price per share consisted of $15.00 per share for 2,000,000 shares and $14.60 per share for 950,000 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by NantCapital, LLC (\"NantCapital\"). California Capital Equity, LLC (\"CalCap\") directly owns all of the equity interests of NantCapital and CalCap may be deemed to have beneficial ownership of the shares held by NantCapital. The reporting person directly owns all of the equity interests of CalCap and has voting and dispositive power over the shares held by CalCap."}],"balance_after":7650000,"source":{"system":"sec-edgar","filing":"0000899243-17-008297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924317008297/doc4.xml","form_type":"4"}},{"id":4435652,"issuer":{"id":138878,"kind":"organization","name":"Tribune Publishing Co","symbol":"TPCO"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-02-21T18:44:05.000Z","date":"2017-02-17","kind":"purchase","acquired":true,"shares":7217,"price":13.91,"value":100388.47,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price reflects the weighted average purchase price per share for the transactions on February 17, 2017. The price per share for such transactions ranged from $13.87 to $13.95. Full information regarding the number of shares sold at each separate price will be provided to the United States Securities and Exchange Commission, the Issuer or a security holder of the Issuer upon a request for such information."}],"balance_after":1093619,"source":{"system":"sec-edgar","filing":"0000899243-17-004805","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924317004805/doc4.xml","form_type":"4"}},{"id":4435651,"issuer":{"id":138878,"kind":"organization","name":"Tribune Publishing Co","symbol":"TPCO"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-02-21T18:44:05.000Z","date":"2017-02-16","kind":"purchase","acquired":true,"shares":6920,"price":13.92,"value":96326.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price reflects the weighted average purchase price per share for the transactions on February 16, 2017. The price per share for such transactions ranged from $13.85 to $13.95. Full information regarding the number of shares sold at each separate price will be provided to the United States Securities and Exchange Commission, the Issuer or a security holder of the Issuer upon a request for such information."}],"balance_after":1086402,"source":{"system":"sec-edgar","filing":"0000899243-17-004805","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924317004805/doc4.xml","form_type":"4"}},{"id":4502297,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman and CEO"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-01-04T22:11:38.000Z","date":"2016-12-30","kind":"gift","acquired":false,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares transferred for no value by Cambridge Equities, LP to the Chan Soon-Shiong NantHealth Foundation, a 501(c)(3) non-profit Delaware corporation."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Cambridge Equities, LP (\"Cambridge Equities\"). MP 13 Ventures, LLC (\"MP 13 Ventures\") is the general partner of Cambridge Equities and may be deemed to have beneficial ownership of the shares held by Cambridge Equities. The reporting person is the sole member of MP 13 Ventures and has voting and dispositive power over the shares held by Cambridge Equities."}],"balance_after":40556557,"source":{"system":"sec-edgar","filing":"0001209191-17-001159","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120919117001159/doc4.xml","form_type":"4"}},{"id":4512364,"issuer":{"id":109592,"kind":"organization","name":"NantHealth, Inc.","symbol":"NHIQ"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman and CEO"}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":2,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"5.50% Convertible Senior Notes due 2021","published_at":"2016-12-23T17:00:15.000Z","date":"2016-12-21","kind":"purchase","acquired":true,"shares":10000000,"price":10000000,"value":100000000000000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The initial conversion rate of the 5.50% Convertible Senior Notes due 2021 (the \"Notes\") is 82.3893 shares of common stock per $1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately $12.14 per share), subject to adjustment pursuant to the terms of the Notes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Notes will be convertible at the option of the reporting persons only upon the satisfaction of certain conditions prior to the close of business on the business day immediately preceding September 15, 2021. Thereafter, the Notes will be convertible at the option of the reporting persons at any time or after September 15, 2021 until the close of business on the business day immediately preceding the maturity date. The Notes will be convertible into cash, shares of the issuer's common stock, or a combination thereof, at the issuer's election."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The initial conversion rate of the 5.50% Convertible Senior Notes due 2021 (the \"Notes\") is 82.3893 shares of common stock per $1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately $12.14 per share), subject to adjustment pursuant to the terms of the Notes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Notes are held by Cambridge Equities, LP (\"Cambridge Equities\"), an entity affiliated with . MP 13 Ventures, LLC (\"MP 13 Ventures\") is the general partner of Cambridge Equities and may be deemed to have beneficial ownership of the option held by Cambridge Equities. The reporting person is the sole member of MP 13 Ventures and has voting and dispositive power over the option held by Cambridge Equities."}],"derivative":{"expiration_date":"2021-12-15","underlying":"Common Stock","underlying_shares":823893},"source":{"system":"sec-edgar","filing":"0000899243-16-036294","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924316036294/doc4.xml","form_type":"4"}},{"id":4525397,"issuer":{"id":138878,"kind":"organization","name":"Tribune Publishing Co","symbol":"TPCO"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-12-12T18:23:18.000Z","date":"2016-12-08","kind":"purchase","acquired":true,"shares":200,"price":13.49,"value":2698.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price reflects the weighted average purchase price per share for the transactions on December 8, 2016. The price per share for such transactions ranged from $13.48 to $13.50. Full information regarding the number of shares sold at each separate price will be provided to the United States Securities and Exchange Commission, the Issuer or a security holder of the Issuer upon a request for such information."}],"balance_after":1079482,"source":{"system":"sec-edgar","filing":"0000899243-16-035324","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924316035324/doc4.xml","form_type":"4"}},{"id":4528439,"issuer":{"id":138878,"kind":"organization","name":"Tribune Publishing Co","symbol":"TPCO"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-12-08T18:38:49.000Z","date":"2016-12-07","kind":"purchase","acquired":true,"shares":19263,"price":13.47,"value":259472.61,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price reflects the weighted average purchase price per share for the transactions on December 7, 2016. The price per share for such transactions ranged from $13.38 to $13.50. Full information regarding the number of shares sold at each separate price will be provided to the United States Securities and Exchange Commission, the Issuer or a security holder of the Issuer upon a request for such information."}],"balance_after":1079282,"source":{"system":"sec-edgar","filing":"0000899243-16-035164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924316035164/doc4.xml","form_type":"4"}},{"id":4528438,"issuer":{"id":138878,"kind":"organization","name":"Tribune Publishing Co","symbol":"TPCO"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-12-08T18:38:49.000Z","date":"2016-12-06","kind":"purchase","acquired":true,"shares":27351,"price":13.37,"value":365682.87,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price reflects the weighted average purchase price per share for the transactions on December 6, 2016. The price per share for such transactions ranged from $13.18 to $13.45. Full information regarding the number of shares sold at each separate price will be provided to the United States Securities and Exchange Commission, the Issuer or a security holder of the Issuer upon a request for such information."}],"balance_after":1060019,"source":{"system":"sec-edgar","filing":"0000899243-16-035164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924316035164/doc4.xml","form_type":"4"}},{"id":4531085,"issuer":{"id":138878,"kind":"organization","name":"Tribune Publishing Co","symbol":"TPCO"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-12-06T18:22:25.000Z","date":"2016-12-05","kind":"purchase","acquired":true,"shares":6151,"price":13.16,"value":80947.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price reflects the weighted average purchase price per share for the transactions on December 5, 2016. The price per share for such transactions ranged from $13.11 to $13.20. Full information regarding the number of shares sold at each separate price will be provided to the United States Securities and Exchange Commission, the Issuer or a security holder of the Issuer upon a request for such information."}],"balance_after":1032668,"source":{"system":"sec-edgar","filing":"0000899243-16-035001","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924316035001/doc4.xml","form_type":"4"}},{"id":4531084,"issuer":{"id":138878,"kind":"organization","name":"Tribune Publishing Co","symbol":"TPCO"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-12-06T18:22:25.000Z","date":"2016-12-02","kind":"purchase","acquired":true,"shares":27754,"price":12.97,"value":359969.38,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price reflects the weighted average purchase price per share for the transactions on December 2, 2016. The price per share for such transactions ranged from $12.85 to $13.05. Full information regarding the number of shares sold at each separate price will be provided to the United States Securities and Exchange Commission, the Issuer or a security holder of the Issuer upon a request for such information."}],"balance_after":1026517,"source":{"system":"sec-edgar","filing":"0000899243-16-035001","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924316035001/doc4.xml","form_type":"4"}},{"id":4536866,"issuer":{"id":138878,"kind":"organization","name":"Tribune Publishing Co","symbol":"TPCO"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-12-01T20:44:25.000Z","date":"2016-12-01","kind":"purchase","acquired":true,"shares":29379,"price":12.77,"value":375169.83,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price reflects the weighted average purchase price per share for the transactions on December 1, 2016. The price per share for such transactions ranged from $12.61 to $13.05. Full information regarding the number of shares sold at each separate price will be provided to the United States Securities and Exchange Commission, the Issuer or a security holder of the Issuer upon a request for such information."}],"balance_after":998763,"source":{"system":"sec-edgar","filing":"0000899243-16-034753","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924316034753/doc4.xml","form_type":"4"}},{"id":4536865,"issuer":{"id":138878,"kind":"organization","name":"Tribune Publishing Co","symbol":"TPCO"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-12-01T20:44:25.000Z","date":"2016-11-29","kind":"purchase","acquired":true,"shares":35643,"price":12.92,"value":460507.56,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price reflects the weighted average purchase price per share for the transactions on November 29, 2016. The price per share for such transactions ranged from $12.76 to $13.00. Full information regarding the number of shares sold at each separate price will be provided to the United States Securities and Exchange Commission, the Issuer or a security holder of the Issuer upon a request for such information."}],"balance_after":969384,"source":{"system":"sec-edgar","filing":"0000899243-16-034753","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924316034753/doc4.xml","form_type":"4"}},{"id":4540957,"issuer":{"id":138878,"kind":"organization","name":"Tribune Publishing Co","symbol":"TPCO"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-28T18:13:24.000Z","date":"2016-11-23","kind":"purchase","acquired":true,"shares":33075,"price":12.94,"value":427990.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price reflects the weighted average purchase price per share for the transactions on November 28, 2016. The price per share for such transactions ranged from $12.83 to $13.00. Full information regarding the number of shares sold at each separate price will be provided to the United States Securities and Exchange Commission, the Issuer or a security holder of the Issuer upon a request for such information."}],"balance_after":933741,"source":{"system":"sec-edgar","filing":"0000899243-16-034451","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1189020/000089924316034451/doc4.xml","form_type":"4"}}],"next_cursor":"2016-11-28T18:13:24.000000Z,4540957"}